Whole-pelvic nodal radiation therapy in the context of hypofractionation for high-risk prostate cancer patients: A step forward

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 4, 2013, Pages 600-605

  Kaidar Person, Orit ^a   Roach III, Mack ^b   Créhange, Gilles ^c  

^a Division of Oncology   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Georges Francois Leclerc Cancer Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; DISEASES; IMAGE ENHANCEMENT; ONCOLOGY; RADIATION; UROLOGY;

CONFORMAL RADIATION THERAPY; CONVENTIONAL RADIATION THERAPY; HIGH-DOSE RATE BRACHYTHERAPY; HIGH-RISK PROSTATE CANCERS; INTENSITY MODULATED RADIATION THERAPY; OVERALL TREATMENT TIME; PROSTATE BRACHYTHERAPY; RADIATION ONCOLOGY;

RADIOTHERAPY;

ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; WHOLE PELVIC RADIATION THERAPY;

EID: 84879238037     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.02.006     Document Type: Review

References (49)

1. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
2. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
3. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
4. J.R. Sathya, I.R. Davis, and J.A. Julian Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate J Clin Oncol 23 2005 1192 1199
5. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239
6. M. Bolla, D. Gonzalez, and P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
7. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
8. A. Pollack, A.L. Hanlon, and E.M. Horwitz Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial Int J Radiat Oncol Biol Phys 64 2006 518 526
9. M. Roach 3rd, M. DeSilvio, and C. Lawton Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413 J Clin Oncol 21 2003 1904 1911
10. D.J. Brenner, and E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095 1101
11. J.F. Fowler Biological factors influencing optimum fractionation in radiation therapy Acta Oncol 40 2001 712 717
12. B. Lennernas, S. Nilsson, and S. Levitt Hypofractionation for radiotherapy of prostate cancer using a low alfa/beta ratio - possible reasons for concerns? An example of five dimensional radiotherapy Acta Oncol 50 Suppl. 1 2011 111 115
13. R. Miralbell, S.A. Roberts, and E. Zubizarreta Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys 82 2012 e17 e24
14. I.R. Vogelius, and S.M. Bentzen Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85 2013 89 94
15. C. Dolinsky, and E. Glatstein Some cases of severe normal tissue toxicity can be anticipated with ablated fractionated radiation with appropriate long-term follow-up Semin Radiat Oncol 18 2008 229 233
16. B. Kavanagh Clinical experience shows that catastrophic late effects associated with ablative fractionation can be avoided by technological innovation Semin Radiat Oncol 18 2008 223 228
17. G. Arcangeli, B. Saracino, and S. Gomellini A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer Int J Radiat Oncol Biol Phys 78 2010 11 18
18. P. Pommier, S. Chabaud, and J.L. Lagrange Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01 J Clin Oncol 25 2007 5366 5373
19. M. Roach 3rd Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials J Clin Oncol 26 2008 3816 3817 author reply 3817-3818
20. M. Roach 3rd, M. DeSilvio, and R. Valicenti Whole-pelvis, "mini-pelvis, " or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial Int J Radiat Oncol Biol Phys 66 2006 647 653
21. S. Arcangeli, B. Saracino, and M.G. Petrongari Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area Radiother Oncol 84 2007 148 155
22. A. Pollack, G. Walker, and M. Buyyounouski Five year results of a randomized external beam radiotherapy hypofractionation trial for prostate cancer Int J Radiat Oncol Biol Phys 81 2011 S1
23. P. Xia, P. Qi, and A. Hwang Comparison of three strategies in management of independent movement of the prostate and pelvic lymph nodes Med Phys 37 2010 5006 5013
24. M. Roach 3rd, B. Pickett, and M. Weil The "critical volume tolerance method" for estimating the limits of dose escalation during three-dimensional conformal radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 35 1996 1019 1025
25. P.A. Kupelian, L. Potters, and D. Khuntia Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer Int J Radiat Oncol Biol Phys 58 2004 25 33
26. G. Crehange, C.P. Chen, and C.C. Hsu Management of prostate cancer patients with lymph node involvement: A rapidly evolving paradigm Cancer Treat Rev 38 2012 956 967
27. A. Wang-Chesebro, P. Xia, and J. Coleman Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer Int J Radiat Oncol Biol Phys 66 2006 654 662
28. T. Guerrero Urbano, V. Khoo, and J. Staffurth Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: Preliminary results of a phase I dose escalation study Clin Oncol (R Coll Radiol) 22 2010 236 244
29. Y. Seo, C.M. Aparici, and C.P. Chen Mapping of lymphatic drainage from the prostate using filtered 99mTc-sulfur nanocolloid and SPECT/CT J Nucl Med 52 2011 1068 1072
30. C.P. Chen, Y. Seo, and K. Shinohara Sentinel lymph node imaging guided IMRT for prostate cancer: Preliminary analysis of a prospective study at UCSF Int J Radiat Oncol Biol Phys 81 2011 S124
31. M. Guckenberger, K. Baier, and A. Richter Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only? Radiat Oncol 3 2008 3
32. J. Yuen, G. Rodrigues, and K. Trenka Comparing two strategies of dynamic intensity modulated radiation therapy (dIMRT) with 3-dimensional conformal radiation therapy (3DCRT) in the hypofractionated treatment of high-risk prostate cancer Radiat Oncol 3 2008 1
33. R. McCammon, K.E. Rusthoven, and B. Kavanagh Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer Int J Radiat Oncol Biol Phys 75 2009 413 420
34. P.A. Kupelian, V.V. Thakkar, and D. Khuntia Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes Int J Radiat Oncol Biol Phys 63 2005 1463 1468
35. P.A. Kupelian, T.R. Willoughby, and C.A. Reddy Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience Int J Radiat Oncol Biol Phys 68 2007 1424 1430
36. T.S. Lim, P.C. Cheung, and D.A. Loblaw Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: Acute toxicity results Int J Radiat Oncol Biol Phys 72 2008 85 92
37. H. Quon, P.C. Cheung, and D.A. Loblaw Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer Int J Radiat Oncol Biol Phys 83 2011 617 623
38. H. Quon, P.C. Cheung, and D.A. Loblaw Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: Late toxicity Int J Radiat Oncol Biol Phys 82 2012 898 905
39. K. Bujko, M.P. Nowacki, and A. Nasierowska-Guttmejer Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer Br J Surg 93 2006 1215 1223
40. B. Cedermark, H. Johansson, and L.E. Rutqvist The Stockholm I trial of preoperative short term radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal Cancer Study Group Cancer 75 1995 2269 2275
41. E. Kapiteijn, C.A. Marijnen, and I.D. Nagtegaal Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer N Engl J Med 345 2001 638 646
42. A. Martling, T. Holm, and H. Johansson The Stockholm II trial on preoperative radiotherapy in rectal carcinoma: Long-term follow-up of a population-based study Cancer 92 2001 896 902
43. M.I. Koukourakis, A. Papadopoulou, and I. Abatzoglou Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer Anticancer Res 32 2012 4561 4568
44. M.I. Koukourakis, S. Touloupidis, and J. Manavis Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: Rationale, technique and early experience Anticancer Res 24 2004 3239 3243
45. T.S. Hong, W.A. Tome, and H. Jaradat Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy Acta Oncol 45 2006 717 727
46. N. Di Muzio, C. Fiorino, and C. Cozzarini Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer Int J Radiat Oncol Biol Phys 74 2009 392 398
47. N. Pervez, C. Small, and M. MacKenzie Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy Int J Radiat Oncol Biol Phys 76 2010 57 64
48. J.B. Adkison, D.R. McHaffie, and S.M. Bentzen Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer Int J Radiat Oncol Biol Phys 82 2012 184 190
49. V. Fonteyne, W. De Gersem, and W. De Neve Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer Int J Radiat Oncol Biol Phys 75 2009 1013 1020